NDSU associate professor of pharmaceutical sciences, Sathish Venkatachalem’s research looks at a key modulator in the body’s environmental interactions in airway inflammation. Venkatachalem said the skill and talent of his research team and collaborators will propel the research forward.
Sathish Venkatachalem, NDSU associate professor of pharmaceutical sciences, was recently awarded a highly competitive, $2.4 million National Institutes of Health grant for research that could help reduce severe asthma symptoms.
Venkatachalem’s research looks at a key modulator in the body’s environmental interactions in airway inflammation. The study, titled “Aryl hydrocarbon receptor signaling in Airway Inflammation,” could help identify novel biomarkers and therapeutic targets for preventing and mitigating symptoms.
“Receiving the NIH R01 grant is an honor and a pivotal moment for our research and lab,” Venkatachalem said. “This funding will provide us necessary resources to explore the complex interactions between AhR signaling and airway inflammation, with the ultimate goal of developing new therapeutic strategies that could significantly improve the quality of life for asthma patients. Additionally, this funding will enable us to conduct comprehensive studies that could uncover new mechanisms behind airway inflammation and remodeling. We are excited about the potential discoveries and the positive impact this research could have on asthma treatment.”
Venkatachalem said the skill and talent of his research team and collaborators will propel the research forward.
“My mentors always said this: You’re only as good as your team. I have an excellent team of lab members who work tirelessly and enthusiastically in our lab,” he said. “In addition, our collaborators, Dr. Rodney D. Britt, co-principal investigator (Nationwide Children's Hospital), and Dr. Christina Pabelick. co-investigator (Mayo Clinic Rochester), will help to achieve our goals for this proposal.”
